SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : IPIC - the obesity pill stock
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: Pat Shields who wrote (83)9/24/1996 3:04:00 AM
From: Anthony Tran   of 113
 
Pat,

I am with you. I am very positive that IPIC will be back to the 30 soon. The reason are:

1) Knoll's product is a phase II/III product; the meeting with FDA will be for the permission to set up a phase III trial; therefore the drug is still 2-3 years prior to PLA approval. Therefore I do not consider this product as near threat. Also since Redux is already on the market any obesity drug will be much harder to get approval.

2) The coming meeting with FDA in November is only a routine post -marketting commitment meeting with the agency.

3) Time magazine mentioned 850,000 new subscription per week; this is a very best new drug introduction.

You will see the short sellers of this stock loose their pants.
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2026 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News